Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again

The Eli Lilly logo appears on the company’s office in San Diego, California, Nov. 21, 2025.Mike Blake | ReutersEli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared again. Despite that strength, sales of its new GLP-1 obesity pill Foundayo, which launched in the U.S. in April, were under Wall Street's expectations for the quarter.The pharmaceutical giant now expects 2026 revenue to come in between $91 billion and $92 billion, up from a previous guidance of $85 billion to $87 billion. Lilly projects its full-year adjusted earnings will be between $35 and $36 per share, which compares with a previous outlook of $35.50 to $36.50 per share. The company said it raised the underlying profit guidance by $4.07 per share at the midpoint, but noted that it is offset by $4.57 per share in charges tied to deals in the quarter.The company's shares rose about 4% in premarket trading.Tune in at 9 a.m. ET as Eli Lilly CEO David Ricks joins CNBC TV to discuss the company's third-quarter earnings. Watch in real time on CNBC+ or the...